Orbital gallium-67 scintigraphy in Graves' ophthalmopathy.
Assessment of orbital disease activity in patients with Graves' ophthalmopathy is important in planning the therapeutic approach. In this study, orbital uptake of gallium-67 citrate ((67)Ga) was evaluated in 46 consecutive patients demonstrating active or inactive Graves' ophthalmopathy. The disease activity with Graves' ophthalmopathy was evaluated by using clinical activity score (CAS). Orbital (67)Ga scintigraphies of 8 patients without any history of ophthalmic, thyroid, or autoimmune disease were studied as controls. (67)Ga scintigraphy was performed 48 hours after intravenous injection of 4 mCi (128 MBq) of radioactive complex. Single-photon emission computed tomography (SPECT) images were obtained with a gamma camera. Intravenous corticosteroid treatment was given to 8 selected patients demonstrating bilateral active orbital disease and (67)Ga scintigraphy was repeated 6 months after the treatment. Quantitative analysis of mean orbital (67)Ga uptake demonstrated significant difference between active, inactive, and control groups (p = 0.0001). The orbital uptake of (67)Ga was significantly elevated in the active group compared to the inactive and control groups. A threshold orbital (67)Ga uptake value was calculated to differentiate active and inactive groups based on receiver operating characteristic (ROC) analysis. A significant correlation was found between the CAS and the (67)Ga orbital uptake (r = 0.73, p = 0.0001). Clinical improvement and significant decrease in orbital (67)Ga uptake were achieved after immunosuppressive treatment (p = 0.0004). These preliminary results suggest that orbital (67)Ga scintigraphy may provide objective assessment of the disease activity in Graves' ophthalmopathy.
Konuk
Onur
O
Department of Ophthalmology, Gazi University Medical School, Beşevler, Ankara, Turkey. acegihkl@ttnet.net.tr
Atasever
Tamer
T
Unal
Mehmet
M
Ayvaz
Göksun
G
Yetkin
Ilhan
I
Cakir
Nuri
N
Arslan
Metin
M
Hasanreisoglu
Berati
B
D000328:Adult; D000368:Aged; D002951:Citrates / Q000493:pharmacokinetics; D035061:Control Groups; D005260:Female; D005708:Gallium / Q000493:pharmacokinetics; D005710:Gallium Radioisotopes / Q000493:pharmacokinetics; D015902:Gamma Cameras; D006111:Graves Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D009915:Orbit / Q000000981:diagnostic imaging* / Q000378:metabolism; D012372:ROC Curve; D015899:Tomography, Emission-Computed, Single-Photon
D002951:Citrates; D005710:Gallium Radioisotopes; D007166:Immunosuppressive Agents; D005708:Gallium; C103850:gallium citrate; D008775:Methylprednisolone